Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…
Sell
49
OCX Quote, Financials, Valuation and Earnings
Last price:
$3.25
Seasonality move
:
-17.73%
Day range:
$3.26 - $3.35
52-week range:
$1.92 - $4.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.10x
P/B ratio:
9.32x
Volume:
38K
Avg. volume:
45.4K
1-year change:
23.79%
Market cap:
$95.2M
Revenue:
$1.9M
EPS (TTM):
-$3.53
Analysts' Opinion
-
Consensus RatingOncoCyte has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.42, OncoCyte has an estimated upside of 62.66% from its current price of $3.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $3.33.
Fair Value
-
According to the consensus of 3 analysts, OncoCyte has 62.66% upside to fair value with a price target of $5.42 per share.
OCX vs. S&P 500
-
Over the past 5 trading days, OncoCyte has overperformed the S&P 500 by 11.62% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
OncoCyte does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
OncoCyte has grown year-over-year revenues for 2 quarters straight. In the most recent quarter OncoCyte reported revenues of $2.1M.
Earnings Growth
-
OncoCyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter OncoCyte reported earnings per share of -$0.26.
Enterprise value:
64.2M
EV / Invested capital:
6.28x
Price / LTM sales:
15.10x
EV / EBIT:
--
EV / Revenue:
16.71x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-2.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2M
Return On Assets:
-93.47%
Net Income Margin (TTM):
-1514.57%
Return On Equity:
-693.81%
Return On Invested Capital:
-693.81%
Operating Margin:
-276.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $875K | $1.4M | $3.8M | $176K | $2.1M | |
| Gross Profit | -$255K | $448K | $2M | $45K | $1.3M | |
| Operating Income | -$27.4M | -$22M | -$23.4M | -$5.8M | -$5.9M | |
| EBITDA | -$409K | -$38.3M | -$56.4M | -$8.8M | -$6.2M | |
| Diluted EPS | -$10.73 | -$5.08 | -$3.53 | -$1.13 | -$0.26 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62.8M | $24.6M | $15.6M | $6.5M | $36.3M | |
| Total Assets | $129.3M | $146.3M | $82.8M | $71M | $60.4M | |
| Current Liabilities | $9.7M | $14M | $9.4M | $8.3M | $9.7M | |
| Total Liabilities | $22.7M | $89.3M | $44.9M | $59.4M | $50.1M | |
| Total Equity | $106.6M | $57M | $37.9M | $11.6M | $10.2M | |
| Total Debt | $3.5M | $945K | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$40.6M | -$18.9M | -$22.7M | -$3.8M | -$5.9M | |
| Cash From Investing | -$4.2M | $416K | -$795K | -$24K | -$307K | |
| Cash From Financing | $36.1M | $12.2M | $49M | -- | $28.6M | |
| Free Cash Flow | -$43.4M | -$19.2M | -$23.5M | -$3.9M | -$6.2M | |
OCX
Sector
Market Cap
$95.2M
$34M
Price % of 52-Week High
70.11%
44.85%
Dividend Yield
0%
0%
Shareholder Yield
-65.08%
-0.66%
1-Year Price Total Return
23.79%
-40.27%
Beta (5-Year)
0.953
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.12
200-day SMA
Buy
Level
$2.83
Bollinger Bands (100)
Buy
Level
2.27 - 3.35
Chaikin Money Flow
Sell
Level
-5.4M
20-day SMA
Buy
Level
$2.98
Relative Strength Index (RSI14)
Buy
Level
60.87
ADX Line
Buy
Level
15.81
Williams %R
Sell
Level
-14.6067
50-day SMA
Buy
Level
$3.03
MACD (12, 26)
Buy
Level
0.07
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
3.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.9544)
Sell
CA Score
(Annual)
Level (-7.3725)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (11.6316)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Stock Forecast FAQ
In the current month, OCX has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The OCX average analyst price target in the past 3 months is $5.42.
-
Where Will OncoCyte Stock Be In 1 Year?
According to analysts, the consensus estimate is that OncoCyte share price will rise to $5.42 per share over the next 12 months.
-
What Do Analysts Say About OncoCyte?
Analysts are divided on their view about OncoCyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OncoCyte is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is OncoCyte's Price Target?
The price target for OncoCyte over the next 1-year time period is forecast to be $5.42 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is OCX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for OncoCyte is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of OCX?
You can purchase shares of OncoCyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OncoCyte shares.
-
What Is The OncoCyte Share Price Today?
OncoCyte was last trading at $3.25 per share. This represents the most recent stock quote for OncoCyte. Yesterday, OncoCyte closed at $3.33 per share.
-
How To Buy OncoCyte Stock Online?
In order to purchase OncoCyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
80
SBET alert for May 29
SharpLink Gaming [SBET] is up 71.47% over the past day.
Buy
100
BOX alert for May 29
Box [BOX] is down 0.76% over the past day.
Sell
22
OKTA alert for May 29
Okta [OKTA] is up 1.65% over the past day.
